---
title: "Leqembi And Skyclarys Expected To Drive Biogen&#39;s Future Growth: Analysts"
date: "2025-02-14 03:30:19"
summary: "Biogen&#39;s Q4 EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers."
categories:
  - "benzinga"
lang:
  - "en"
translations:
  - "en"
tags:
  - "benzinga"
menu: ""
thumbnail: "https://www.benzinga.com/files/images/story/2025/02/13/Cambridge--Ma--Usa---June-29--2022-Bioge_0.jpeg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Biogen's Q4 EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.

[benzinga](https://www.benzinga.com/25/02/43708416/leqembi-and-skyclarys-expected-to-drive-biogens-future-growth)
